ICCC enters its Q1 2026 earnings release — due after the bell on May 14 — carrying two pieces of fresh corporate news that together reframe the entire investment case.
The most significant development broke this week: ImmuCell reached a $2 million settlement with Norbrook Laboratories following the expiration of a 2019 supply agreement. For a company with a market cap around $73 million, a $2M cash receipt is material. It landed on the same day the stock dropped nearly 5%, closing at $8.05 on May 8 — a week that saw a total decline of 7.8%. That tension between a positive corporate resolution and a falling stock is the central setup going into next week's print.
Short interest here is barely worth naming as a driver. At just 0.27% of the free float — down 6.6% on the week and nearly 16% over the past month — there is virtually no short-side pressure on this stock. Borrowing costs, at 5.7%, have actually risen a touch this week after troughing earlier in May, but they remain well below the highs above 9% seen in late March. Borrow availability is essentially unlimited: the availability-to-short-interest ratio is running at the ceiling, meaning the lending market has no real role in this story. The ORTEX short score of 30.9 sits in a modest range, and with the borrow market this relaxed, the short positioning angle is firmly a sideshow.
What does deserve attention is the deeper governance shift unfolding at ImmuCell. Late April brought a 30% stock rally alongside CEO changes and new board appointments — a reshaping that the company framed as advancing its innovation strategy. The former CEO, Michael Brigham, sold 24,052 shares at $6.07 in March, pocketing roughly $146,000 as that transition played out. His predecessor in the role, Paul Te Boekhorst, had been a consistent buyer in late 2025, picking up nearly 9,700 shares across three December sessions in the $4.87–$5.50 range. Independent Chairman David Tomsche has also been a steady buyer going back to mid-2024. The net insider picture over 90 days is therefore one of a departing CEO liquidating, surrounded by a board that has been adding at lower prices — a pattern worth watching as the new management team settles in.
The ownership structure is concentrated in a small number of hands. The Pessin family collectively accounts for roughly 13.1% of shares, with Norman Pessin reducing his position significantly in the latest filing. SRK Capital and Jonathan Rothschild each hold around 5.5–5.7%. Vanguard and Renaissance Technologies have small but present positions, suggesting some passive and quantitative interest. With only 36 institutional holders in total, liquidity and any meaningful ownership shift can move the needle quickly.
The last earnings print, for Q4 2025, revealed a net loss of $2.85 million for the quarter versus net income of $0.52 million a year prior — a meaningful deterioration year-on-year. The full-year 2025 loss narrowed to $1.04 million from $2.16 million in 2024, but the Q4 gap will likely frame the bar for Q1. Price reactions to recent results have been muted: the stock barely moved on the last print, with a one-day move of under 1% in either direction and a five-day drift of 2–4%. That historical restraint is notable context as the stock re-approaches earnings at $8.05, up roughly 22% on the month but giving back a week's gains.
The next marker is straightforward: May 14 brings Q1 results, and May 15 the earnings call, where management's tone on the Norbrook settlement proceeds and the post-governance-change revenue outlook will be the primary points of focus.
See the live data behind this article on ORTEX.
Open ICCC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
